MPM BioImpact Portfolio holdings
MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALX Oncology
ALXO
|
+$12M |
| 2 |
Morphic Holding
MORF
|
+$2.95M |
| 3 |
Disc Medicine
IRON
|
+$2.56M |
| 4 |
MoonLake Immunotherapeutics
MLTX
|
+$19.9K |
| 5 |
Insmed
INSM
|
+$17.9K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$5.57M |
| 2 |
Travere Therapeutics
TVTX
|
+$4.94M |
| 3 |
Intellia Therapeutics
NTLA
|
+$4.66M |
| 4 |
Relay Therapeutics
RLAY
|
+$4.39M |
| 5 |
Verve Therapeutics
VERV
|
+$2.72M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
Similar funds
MPM BioImpact's Q4 2023 Portfolio in Review
As of Q4 2023, MPM BioImpact held 34 positions worth $427M, up 14% from $375M the previous quarter. Its ten largest holdings account for 61% of the portfolio.
MPM BioImpact's Q4 2023 filing shows 2 new, 10 increased, 13 reduced and 2 closed positions. Its largest new stake was ALX Oncology: 1,264,759 shares worth $18.8M. The largest sale was KalVista Pharmaceuticals, an estimated $5.57M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
- MPM BioImpact's largest Q4 2023 buy was ALX Oncology: 1,264,759 shares worth $18.8M.
- MPM BioImpact added most to Morphic Holding in Q4 2023, an estimated $2.95M increase.
- MPM BioImpact's biggest Q4 2023 reduction was Intellia Therapeutics, cutting an estimated $4.66M.
- MPM BioImpact fully exited KalVista Pharmaceuticals in Q4 2023, selling an estimated $5.57M.
- MPM BioImpact's ten largest holdings make up 61% of its $427M portfolio in Q4 2023.
- MPM BioImpact opened 2 new positions and closed 2 in Q4 2023.
- MPM BioImpact's portfolio value rose 14% quarter-over-quarter to $427M.
Based on MPM BioImpact's 13F filing for Q4 2023, filed 13 Feb 2024.